IL231951B - pam3cys-like stimulants and their use for the preparation of preparations - Google Patents

pam3cys-like stimulants and their use for the preparation of preparations

Info

Publication number
IL231951B
IL231951B IL231951A IL23195114A IL231951B IL 231951 B IL231951 B IL 231951B IL 231951 A IL231951 A IL 231951A IL 23195114 A IL23195114 A IL 23195114A IL 231951 B IL231951 B IL 231951B
Authority
IL
Israel
Prior art keywords
pam3cys
medicaments
manufacture
adjuvant compounds
adjuvant
Prior art date
Application number
IL231951A
Other languages
English (en)
Hebrew (he)
Other versions
IL231951A0 (en
Inventor
Antonius Ossendorp Ferdinand
Johannes Maria Melief Cornelis
Khan Selina
Viktorovitsj Filippov Dmitri
Arie Van Der Marel Gijsbert
Original Assignee
Isa Pharmaceuticals B V
Antonius Ossendorp Ferdinand
Johannes Maria Melief Cornelis
Khan Selina
Viktorovitsj Filippov Dmitri
Arie Van Der Marel Gijsbert
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isa Pharmaceuticals B V, Antonius Ossendorp Ferdinand, Johannes Maria Melief Cornelis, Khan Selina, Viktorovitsj Filippov Dmitri, Arie Van Der Marel Gijsbert filed Critical Isa Pharmaceuticals B V
Publication of IL231951A0 publication Critical patent/IL231951A0/en
Publication of IL231951B publication Critical patent/IL231951B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
IL231951A 2011-10-05 2014-04-03 pam3cys-like stimulants and their use for the preparation of preparations IL231951B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161543510P 2011-10-05 2011-10-05
NL2007536A NL2007536C2 (en) 2011-10-05 2011-10-05 Adjuvant compound.
US201261615566P 2012-03-26 2012-03-26
PCT/NL2012/050694 WO2013051936A1 (en) 2011-10-05 2012-10-04 Adjuvant compound

Publications (2)

Publication Number Publication Date
IL231951A0 IL231951A0 (en) 2014-05-28
IL231951B true IL231951B (en) 2019-08-29

Family

ID=48043964

Family Applications (1)

Application Number Title Priority Date Filing Date
IL231951A IL231951B (en) 2011-10-05 2014-04-03 pam3cys-like stimulants and their use for the preparation of preparations

Country Status (16)

Country Link
US (2) US9314521B2 (enExample)
EP (1) EP2763697B9 (enExample)
JP (1) JP6099210B2 (enExample)
KR (1) KR102053699B1 (enExample)
CN (1) CN104244976B (enExample)
AU (1) AU2012319265B2 (enExample)
BR (1) BR112014008214B1 (enExample)
CA (1) CA2886631C (enExample)
EA (1) EA030741B1 (enExample)
ES (1) ES2952644T3 (enExample)
IL (1) IL231951B (enExample)
IN (1) IN2014DN03325A (enExample)
MX (1) MX356028B (enExample)
NL (1) NL2007536C2 (enExample)
SG (1) SG11201401291XA (enExample)
WO (1) WO2013051936A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE034308T2 (en) 2013-03-21 2018-02-28 Sanofi Aventis Deutschland Preparation of hydantoin-containing peptide products
US10450343B2 (en) 2013-03-21 2019-10-22 Sanofi-Aventis Deutschland Gmbh Synthesis of cyclic imide containing peptide products
CN105555756B (zh) 2013-06-28 2018-12-07 奥克兰联合服务有限公司 氨基酸缀合物和肽缀合物及缀合方法
WO2015187009A1 (en) 2014-06-02 2015-12-10 Isa Pharmaceuticals B.V. Synthetic long peptides (slp) for therapeutic vaccination against hepatitis b virus infection
CA2971677A1 (en) 2014-12-23 2016-06-30 Margaret Anne Brimble Amino acid and peptide conjugates and uses thereof
MY196837A (en) 2015-12-11 2023-05-03 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers
GB201521894D0 (en) * 2015-12-11 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers
TW201735952A (zh) 2016-02-26 2017-10-16 瑪格蕾特 安 布萊博 胺基酸及肽共軛物以及共軛過程
CN117018170A (zh) 2016-06-20 2023-11-10 Isa制药有限公司 肽疫苗制剂
BR112019000071A2 (pt) 2016-07-07 2019-07-02 Bolt Biotherapeutics Inc conjugados adjuvantes de anticorpo
JP2020515629A (ja) 2017-04-04 2020-05-28 アヴィディア テクノロジーズ, インコーポレイテッド 免疫応答を誘導するためのペプチドベースのワクチン、それらの製造方法および使用
WO2019122050A1 (en) 2017-12-22 2019-06-27 Isa Pharmaceuticals B.V. Methods of immunization
EP3937984A1 (en) 2019-03-15 2022-01-19 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
EP4069271A1 (en) 2019-12-07 2022-10-12 ISA Pharmaceuticals B.V. Treatment of diseases related to hepatitis b virus
EP4100051A2 (en) 2020-02-07 2022-12-14 ISA Pharmaceuticals B.V. Treatment of hpv-related diseases
EP4138876A1 (en) 2020-04-23 2023-03-01 ISA Pharmaceuticals B.V. Immunization against sars-cov-related diseases
CA3223357A1 (en) 2021-07-12 2023-01-19 Brigitte Elisa Anna Burm Improved substance quantification in complex mixtures
WO2024068636A1 (en) 2022-09-27 2024-04-04 Isa Pharmaceuticals B.V. Adjuvanted immunogenic peptides for intradermal administration
WO2024079311A1 (en) 2022-10-13 2024-04-18 Isa Pharmaceuticals B.V. Modified long peptides suitable for use in immunisation
AU2023367780A1 (en) 2022-10-25 2025-03-27 Barinthus Biotherapeutics North America, Inc. Self-assembling nanoparticles
WO2024149888A1 (en) 2023-01-12 2024-07-18 Isa Pharmaceuticals B.V. Improved lipopeptide quantification
WO2025008085A1 (en) 2023-07-05 2025-01-09 Isa Pharmaceuticals B.V. Immunotherapy for the treatment of prame-expressing cancers

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE67769T1 (de) * 1983-01-25 1991-10-15 Ciba Geigy Ag Neue peptidderivate.
DE3937412A1 (de) * 1989-11-10 1991-05-16 Hoechst Ag Synthetische vakzine zur spezifischen induktion zytotoxischer t-lymphozyten
US6024964A (en) * 1985-06-24 2000-02-15 Hoechst Aktiengesellschaft Membrane anchor/active compound conjugate, its preparation and its uses
US5804381A (en) 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
US6504010B1 (en) 1999-06-30 2003-01-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030211510A1 (en) 1999-06-30 2003-11-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
EP1196565A2 (en) 1999-06-30 2002-04-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6686447B1 (en) 1999-06-30 2004-02-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
NL1012739C2 (nl) 1999-07-29 2001-01-30 Maasland Nv Voerinrichting, in het bijzonder voor het verstrekken van krachtvoer.
ES2724121T3 (es) 2000-12-08 2019-09-06 Academisch Ziekenhuis Leiden Péptidos largos de 22-45 residuos de aminoácidos que inducen y/o mejoran las respuestas inmunológicas específicas para antígenos
MXNL04000056A (es) 2004-06-30 2006-01-11 Mario Alberto Aguilera Rico Sistema de construccion terra acero.
CA2660830A1 (en) * 2006-08-14 2008-02-21 Gideon Goldstein Compositions and methods for the treatment and prophylaxis of multiple strains and subtypes of hiv-1
EP3533461A3 (en) 2007-03-26 2019-12-18 Academisch Ziekenhuis Leiden h.o.d.n. LUMC Prame derived peptides and immunogenic compositions comprising these
AU2008257791B2 (en) 2007-05-31 2013-03-28 Academisch Ziekenhuis Leiden H.O.D.N. Lumc P53 peptide vaccine
EP2468763B1 (en) 2007-05-31 2014-06-18 Academisch Ziekenhuis Leiden h.o.d.n. LUMC HPV epitopes targeted by T cells infiltrating cervical malignancies for use in vaccines
KR100900837B1 (ko) 2007-12-07 2009-06-04 (주)두비엘 리포펩타이드와 폴리(i:c)를 아쥬반트로 포함하는 강력한백신 조성물
EA031379B1 (ru) * 2010-03-23 2018-12-28 Новартис Аг Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний

Also Published As

Publication number Publication date
JP2014530808A (ja) 2014-11-20
US20160250325A1 (en) 2016-09-01
BR112014008214B1 (pt) 2022-07-05
JP6099210B2 (ja) 2017-03-22
IN2014DN03325A (enExample) 2015-06-26
CN104244976B (zh) 2017-05-31
MX2014004114A (es) 2014-10-17
EA030741B1 (ru) 2018-09-28
EP2763697B1 (en) 2023-06-07
NL2007536C2 (en) 2013-04-08
EP2763697A1 (en) 2014-08-13
NZ623869A (en) 2015-11-27
KR20140093673A (ko) 2014-07-28
CN104244976A (zh) 2014-12-24
EP2763697B8 (en) 2023-07-12
CA2886631C (en) 2019-06-11
EP2763697B9 (en) 2023-10-04
US9770506B2 (en) 2017-09-26
AU2012319265A1 (en) 2014-05-22
EA201490709A1 (ru) 2014-09-30
ES2952644T3 (es) 2023-11-02
US9314521B2 (en) 2016-04-19
KR102053699B1 (ko) 2019-12-09
WO2013051936A1 (en) 2013-04-11
BR112014008214A2 (pt) 2017-06-13
WO2013051936A9 (en) 2013-09-12
EP2763697C0 (en) 2023-06-07
IL231951A0 (en) 2014-05-28
CA2886631A1 (en) 2013-04-11
AU2012319265B2 (en) 2016-10-13
MX356028B (es) 2018-05-09
SG11201401291XA (en) 2014-05-29
US20150104473A1 (en) 2015-04-16

Similar Documents

Publication Publication Date Title
IL269054A (en) A pharmaceutical preparation containing tesimaltone for use in the treatment of 24-NON
EP2739144A4 (en) COMPOUNDS AND ITS THERAPEUTIC USE
EP2542086A4 (en) COMPOUNDS AND ITS THERAPEUTIC USE
PL2934404T3 (pl) Elastyczny laminat i sposób wytwarzania elastycznego laminatu
EP2668177A1 (en) Substituted pyridinyl-pyrimidines and their use as medicaments
GB201120993D0 (en) Novel compounds and their use in therapy
IL229844B (en) Anti-psgl-1 antibodies and their use
ZA201403372B (en) Therapeutic agents and uses thereof
EP2867209A4 (en) COMPOUNDS AND THEIR THERAPEUTIC USES
EP2840938A4 (en) THERAPEUTIC CUSHION
IL231082A0 (en) Pyrimido-pyridazinone compounds and their use
IL233825A (en) H1-indazole-3-carboxamide compounds, preparations containing them and their use in the preparation of medicines
PL2723311T3 (pl) Sposoby wytwarzania kompozycji kosmetycznej zawierającej leukolektynę i jej zastosowania
GB201419145D0 (en) Process for the manufacture of a polypropylene-paper laminate and polypropylene-paper lamianate
SG10201604468QA (en) Shk-based pharmaceutical compositions and methods of manufacturing and using the same
GB201111775D0 (en) Compounds and uses thereof
AU2011904672A0 (en) Therapeutic Compounds and Uses Thereof
GB201121726D0 (en) Compounds and uses thereof
GB201121551D0 (en) Compounds and uses thereof
AU2012904991A0 (en) Therapeutic Compounds and Uses Thereof
GB201005712D0 (en) Medicaments and their manufacture
GB201104875D0 (en) New compounds and medical uses
GB201104872D0 (en) New compounds and medical uses
GB201102227D0 (en) Inventions and therapy
GB201102222D0 (en) Inventions and therapy

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed